ML385

Item no.	HY-100523-1mg
Manufacturer	MedChem Express
CASRN	846557-71-9
Amount	1 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 200 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Compound Libraries
Specific against	other
Purity	99.96
Citations	[1]Singh A, et al. Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors. ACS Chem Biol. 2016 Nov 18;11(11):3214-3225. [2]Xinnong Liu, et al. Isoliquiritigenin ameliorates acute pancreatitis in mice via inhibition of oxidative stress and modulation of the Nrf2/HO-1 pathway. Oxid Med Cell Longev. 20 March 2018. [3]Xian P, et al. Mesenchymal stem cell-derived exosomes as a nanotherapeutic agent for amelioration of inflammation-induced astrocyte alterations in mice.Theranostics. 2019 Aug 14;9(20):5956-5975.
Smiles	O=C(NC1=NC(C2=CC=C(N(C(C3=C(C)C=CC=C3)=O)CC4)C4=C2)=C(C)S1)CC5=CC(OCO6)=C6C=C5
Shipping condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Ferroptosis; Keap1-Nrf2
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	511.59
Product Description	ML385 is a specific nuclear factor erythroid 2-related factor 2 (NRF2) inhibitor with an IC50 of 1.9 μM.
Manufacturer - Research Area	Cancer
Solubility	DMSO : 25 mg/mL (ultrasonic)\|H2O : < 0.1 mg/mL
Manufacturer - Pathway	Apoptosis; NF-κB
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-100523-1mg-safety-datasheet.pdf